Skip to main content

TWST

Stock

TWST

Stock
Health Care
Diagnostics & Research

Performance overview

TWST Price
Price Chart

Forward-looking statistics

Beta
1.82
Risk
67.73%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees978
Market cap$2.9B

Fundamentals

Enterprise value$2.0B
Revenue$347.7M
Revenue per employee
Profit margin-54.98%
Debt to equity18.25

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.25
Dividend per share
Revenue per share$5.90
Avg trading volume (30 day)$41M
Avg trading volume (10 day)$32M
Put-call ratio

Macro factor sensitivity

Growth-0.6
Credit+6.9
Liquidity-0.1
Inflation-4.2
Commodities+1.3
Interest Rates-4.2

Valuation

Dividend yield0.00%
PEG Ratio-15.07
Price to sales6.31
P/E Ratio-15.07
Enterprise Value to Revenue5.83
Price to book4.98

Upcoming events

Next earnings dayMay 5, 2025
Next dividend day
Ex. dividend day

News

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago.

Zacks Investment Research (May 5, 2025)
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps

On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.

Benzinga (November 18, 2024)
Synthetic Biology: Twist Bioscience Revenue Growing From $2 To $200 Million As It Eyes The $186 Billion Antibody Market

The biggest reason why Twist is currently valued at $1.9 billion is the potential to use their silicon DNA synthesis platform for the discovery of new drugs.

Forbes (November 2, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free